.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,994,220

« Back to Dashboard
Patent 7,994,220 protects SAVELLA and is included in one NDA. There has been one Paragraph IV challenge on Savella. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has twenty-eight patent family members in twenty-one countries.

Summary for Patent: 7,994,220

Title:Milnacipran for the long-term treatment of fibromyalgia syndrome
Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
Inventor(s): Rao; Srinivas G. (Encinitas, CA), Gendreau; Michael (Poway, CA), Kranzler; Jay D. (La Jolla, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:11/535,237
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 135th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-001Jan 14, 2009RXNo7,994,220► subscribe MANAGEMENT OF FIBROMYALGIA
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-002Jan 14, 2009RXNo7,994,220► subscribe MANAGEMENT OF FIBROMYALGIA
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-003Jan 14, 2009RXYes7,994,220► subscribe MANAGEMENT OF FIBROMYALGIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,994,220

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2012193216► subscribe
Japan5922515► subscribe
Japan2009510080► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc